louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05451706: Improving College Students' Mental Help-Seeking Intention During the COVID-19 Pandemic
Official title: Improving College Students' Mental Help-Seeking Intention During the COVID-19 Pandemic
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Help-Seeking Behavior
Mental Health Issue
Keywords: Mental help-seeking
COVID-19
College students
Self-persuasion
Lead sponsor: Cleveland State University
Sponsor class: OTHER
First posted: 2022-07-11
Enrollment: 926
Sex: ALL
Minimum age (years): 18
Maximum age (years): 100
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: This study aimed at testing the effectiveness of a longitudinal intervention in increasing college students' intention to seek mental help during the pandemic.

Detailed description: This study aimed at testing the effectiveness of a longitudinal intervention in increasing college students' intention to seek mental help during the pandemic.

A four-armed randomized controlled experiment was conducted to compare two self-persuasion methods against two control conditions. Assessments took place at baseline (T0), post-first treatment (T1), post-second treatment (six weeks, T2), and ten-week follow-up (T3).

The results showed that the intervention significantly increased students' help-seeking intention, attitude, and efficacy at different time points. It also reduced mental help-seeking-related stigma after the first task.

Eligibility criteria: Inclusion Criteria:

* 18 years old or older
* Full-time undergraduate students
* Had more than a moderate amount of mental distress

Exclusion Criteria:

* Under 18 years old
* Not full-time undergraduate students
* Had less than a moderate amount of mental distress

Primary outcomes:
measure: Help-Seeking Intention
timeFrame: 10 weeks
measure: Help-Seeking Behavior
timeFrame: 10 weeks
Secondary outcomes:
measure: Mental help-seeking attitudes
timeFrame: 10 weeks
measure: Self-stigma of seeking mental help
timeFrame: 10/2020 - 1/10 weeks
measure: Mental help-seeking efficacy
timeFrame: 10 weeks
Other outcomes:
Locations:
city: College Station
country: United States
facility: Texas A&M University
state: Texas
Study officials:
affiliation: Cleveland State University
name: Qiwei Wu
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04762706: Measuring Distress in Prosthetic Joint Infection Using a Standardized Metric: CRUTCH Pathway Pilot.
Official title: Treating the Whole Patient: Measuring Distress in Prosthetic Joint Infection Using a Standardized Metric: CRUTCH Pathway Pilot.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Prosthetic Joint Infection
Lead sponsor: West Virginia University
Sponsor class: OTHER
First posted: 2021-02-21
Enrollment: 9
Sex: ALL
Minimum age (years): 18
Maximum age (years): 89
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: SUPPORTIVE_CARE

Brief summary: The purpose of this study is to determine whether patients being treated for prosthetic joint infections (PJI) experience distress during the course of their treatment and how distress influences various aspects of their lives. WVU expects to enroll approximately 12 subjects. Patients identified as scoring ≥4 on the Distress Thermometer at the two-week follow-up visit will be offered the opportunity to participate in the novel CRUTCH Pathway. Once enrolled, you will meet virtually with a mental health provider. The mental health provider will complete a 30-minute intake visit where he will review your distress thermometer scoring, discuss contributing factors to current distress level, and assess for psychiatric comorbidities.


Eligibility criteria: Inclusion Criteria:

* ability to speak and read English, and cognitively sound. Patients scheduled for revision of total hip or knee arthroplasty will be categorized as septic or aseptic revisions. Patients identified as scoring ≥4 on the DT at the two-week follow-up visit.

Exclusion Criteria:

* Patients younger than 18 or older than 89, patients unable to speak and/or read English, and patients who are not able to understand and answer questions asked on surveys. Elective primary total hip or knee arthroplasty, hemiarthroplasty, unicompartmental knee arthroplasty.

Primary outcomes:
measure: Assess patient experience with a Distress Thermometer and Problem List
timeFrame: Two week post operative
Secondary outcomes:
Other outcomes:
Locations:
city: Morgantown
country: United States
facility: WVU Medicine University Town Center
state: West Virginia
Study officials:
affiliation: West Virginia University
name: Allison Lastinger, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01265706: Livalo Acute Myocardial Infarction Study (LAMIS)
Official title: 1-year, Prospective, Randomized, Open-label, Parallel Group Observational Study to Evaluate the Safety and Efficacy of 4mg/Day of Pitavastatin Versus 2mg/Day of Pitavastatin in Acute Myocardial Infarction(AMI)
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Acute Myocardial Infarction
Keywords: Hydroxymethylglutaryl-CoA Reductase Inhibitors
Lead sponsor: JW Pharmaceutical
Sponsor class: INDUSTRY
First posted: 2010-12-23
Enrollment: 1000
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: AMI patients who are in need to be treated by statins

Brief summary: This study is performed to observe the incidence of major cardiovascular events in Korean patients with AMI after giving pitavastatin 2mg and 4mg longer than 1 year.


Eligibility criteria: Inclusion Criteria:

* Patients with STEMI, NSTEMI
* Patients satisfying at least one of the followings

  1. Patients with LDL-C ≥ 130 mg/dL
  2. Patients with LDL-C ≥ 100 mg/dL who are regarded as required cholesterol lowering therapy by the investigator
  3. Patients taking statin are required continuous cholesterol lowering therapy
* Patients satisfying at least two of the followings

  1. The change of Ischemic ECG
  2. CK, CK-MB, Troponin-I increased more than two times
  3. The symptom of ACS

Exclusion Criteria:

1. Patients with in-stent restenosis after PCI or coronary artery bypass
2. Patients with cardiogenic shock
3. Patients with severe heart failure (Left ventricular ejection fraction is less than 30%)
4. Patients who are taking cyclosporine
5. Patients who experienced hypersensitivity to pitavastatin
6. Patients under dialysis treatment
7. Patients who are participating other clinical trials
8. Patients who can not stop taking concomitant drugs
9. Pregnant or lactating women or suspected pregnancy
10. Patients who are regarded as ineligible for this study by the investigator

Primary outcomes:
measure: Incidence of TLR-MACE for 1 year after enrollment
timeFrame: 1 year after enrollment
Secondary outcomes:
measure: Incidence of TVR-MACE for 1 year after enrollment
timeFrame: 1 year after enrollment
Other outcomes:
Locations:
city: Gwangju
country: Korea, Republic of
facility: Chonnam National University Hospital
Study officials:
affiliation: Chonnam National University Hospital
name: Young Jun Hong
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01160406: Screening for Atrial Fibrillation, After Ischemic Stroke
Official title: Improving Screening for Silent Atrial Fibrillation, After Ischemic Stroke
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Atrial Fibrillation
Stroke
Keywords: silent paroxysmal atrial fibrillation
stroke
tele ECG
Lead sponsor: Karolinska Institutet
Sponsor class: OTHER
First posted: 2010-07-12
Enrollment: 250
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients from hospital strokewards.

Brief summary: The aim of the study is to assess the incidence of patients suffering from ischemic stroke or transient ischemic attacks who have underlying asymptomatic paroxysmal atrial fibrillation.

Patients who have suffered an ischemic stroke or transient ischemic attack, without a history of atrial fibrillation, are planned to be included. Starting within 14 days of the ischemic stroke, participating patients are asked to perform 10 second ECG recordings using a handheld ECG device twice daily (mornings and evenings) during 30 days. These recordings are transmitted via telephone to a secure encrypted Internet site. Within these 30 days the participants also perform an ambulatory 24 hour Holter recording. Handheld ECG recordings are evaluated continuously. In case of atrial fibrillation the patient is informed and offered treatment with anti coagulant medication (Warfarin). The investigation is a comparison between 24 hour continuous ECG recordings and short intermittent ECG recordings twice daily over a longer time period to determine which method is the best to detect atrial fibrillation in this patient group.

Hypothesis: Short Intermittent ECG recordings over a longer time period is more efficient, compared with continuous 24 hour ECG recordings, in detecting silent paroxysmal AF in patients with an ischemic stroke and without a history of atrial fibrillation.


Eligibility criteria: Inclusion Criteria:

* No previously diagnosed atrial fibrillation.
* Acute ischemic stroke or transient ischemic attack verified by computed tomography or clinical diagnosis using the National Institute of Health Stroke Score within 14 days of enrollment.
* Ability to understand study instructions both verbal and written.
* Ability to perform and transmit ECG recordings according to study design.

Exclusion Criteria:

* Previously diagnosed atrial fibrillation.
* Hemorrhagic stroke
* Low compliance
* Pacemaker carrier

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Halmstad
country: Sweden
facility: Halmstad hospital
state: Halland
city: Stockholm
country: Sweden
facility: South hospital
city: Stockholm
country: Sweden
facility: Danderyds hospital AB
Study officials:
affiliation: Karolinska Institutet
name: Mårten Rosenqvist, M.D.Ph.D.
role: STUDY_DIRECTOR
References:
Clinical trial NCT04424706: The Effect and Mechanism of MMP-9 in Inducing Atherosclerosis
Official title: The Effect and Mechanism of MMP-9 in Inducing Atherosclerosis in Type 2 Diabetes
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Type 2 Diabetes
Lead sponsor: Nanjing First Hospital, Nanjing Medical University
Sponsor class: OTHER
First posted: 2020-06-11
Enrollment: 180
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Normal control group, newly diagnosis of type 2 diabetes mellitus with atherosclerosis, newly diagnosis of type 2 diabetes mellitus without atherosclerosis

Brief summary: The study will assess the serum expression of MMP-9 in normal people, type 2 diabetic patients and type 2 diabetic patients with atherosclerosis.


Eligibility criteria: Inclusion Criteria:

* volunteer to participate and be able to sign informed consent prior to the trial.
* patients with type 2 diabetes, aged 18-60 years old, meeting WHO1999 diagnostic criteria, have not used any drugs.
* The patients have completed carotid ultrasound during hospitalization.

Exclusion Criteria:

* patients with any antidiabetic drugs.
* impaired liver and kidney function with ALT 2.5 times higher than the upper limit of normal value; Serum creatinine was 1.3 times higher than the upper limit of normal.
* drug abuse and alcohol dependence in the past 5 years.
* systemic hormone therapy was used in the last three months.
* patients with infection and stress within 4 weeks.
* any other obvious conditions or associated diseases determined by the researcher: such as severe cardiopulmonary diseases, endocrine diseases, neurological diseases, tumors and other diseases, other pancreatic diseases, history of mental diseases.

Primary outcomes:
measure: total MMP-9 levels
timeFrame: 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Nanjing
country: China
facility: Nanjing First Hospital
state: Jiangsu
Study officials:
References:
Clinical trial NCT05527106: Evaluation of the Effect of Citicoline and Docosahexaenoic Acid (DHA) on the Visual Function of Patients With Glaucoma
Official title: Evaluation of the Effect of Citicoline (Cebrolux 800 mg) and Docosahexaenoic Acid (DHA) Compound (BrudyPio 1.5 g) on the Visual Function of Patients With Glaucoma With a Pilot Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Glaucoma
Keywords: glaucoma
nutraceuticals
dha (docosahexaenoic acid)
citicoline
Lead sponsor: Institut Catala de Retina
Sponsor class: OTHER
First posted: 2022-09-02
Enrollment: 73
Sex: ALL
Minimum age (years): 50
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: Pilot, single-blind, randomized and controlled study to evaluate the changes produced in the visual function of patients with glaucoma after oral administration for 3 months of citicoline and docosahexaenoic Acid (DHA) vs citicoline and docosahexaenoic Acid (DHA) vs vitamin C.


Eligibility criteria: Inclusion Criteria:

1. Patients with chronic, primary or secondary, open or closed angle glaucoma, diagnosed by meeting the following criteria:

   * Signs of structural damage: thinning of the optical nerve or peripapillary hemorrhage or decrease in the nerve fiber layer that can be seen by OCT.
   * Signs of functional damage: 3 points outside 95% of the normal limit on the visual field pattern deviation graph.
2. There must be at least 3 reliable visual fields prior to the start of the study.
3. Patients between 50 and 75 years old, homogeneously distributed among the groups.
4. Glaucoma with functional and structural damage.

   * Medium grade, Mean Deviation (MD) between -4 and -20 dB.
   * In at least one eye.

Exclusion Criteria:

1. Treatment with some other vitamin or nutraceutical preparation.
2. Any pathology that can alter the visual field. (Neurological diseases, retinopathies, advanced cataract, patients treated with lyrica (due to the affectation it produces in the visual field)).
3. Hypersensitivity to aspirin. (Cross-allergic reaction has been reported in patients taking citicoline.)
4. Allergic to fish protein.
5. Eye surgery in the 3 months before or during the study.

Primary outcomes:
measure: Effect on Mean Defect (MD)
timeFrame: From Baseline to Month 3.
measure: Effect on Visual Field Index (VFI)
timeFrame: From Baseline to Month 3.
Secondary outcomes:
measure: Evaluation of the changes produced in the intraocular pressure (IOP)
timeFrame: From Baseline to Month 3.
measure: Evaluation of tolerance
timeFrame: From Month 1 to Month 3
Other outcomes:
Locations:
city: Barcelona
country: Spain
facility: Institut Catala de Retina
Study officials:
affiliation: Institut Catala de Retina
name: Alfonso Anton, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02915406: cliniMACs HUD for T Cell Depletion
Official title: cliniMACs HUD for T Cell Depletion
Study type: EXPANDED_ACCESS
Overall status: NO_LONGER_AVAILABLE
Conditions: x Linked Combined Immunodeficiency
Lead sponsor: University of Miami
Sponsor class: OTHER
Collaborators: name: Jackson Health System
First posted: 2016-09-27
Sex: ALL
Maximum age (years): 65
Standard ages: CHILD
ADULT
OLDER_ADULT

Brief summary: This protocol is designed to enable access to related or unrelated CD34 cells manufactured using the CliniMACS (Miltenyi) under the HUD designation for patients needing T cell depleted allogeneic grafts for hematopoietic stem cell transplant (HSCT). This will include patients with inherited immunodeficiency disorders as well as patients with malignancies, bone marrow failure, and other rare diseases amenable to HSCT. Finally, patients with poor graft function and Graft Versus Host Disease(GVHD) after a previous HSCT may require a boost of T-cell depleted donor Peripheral Blood Stem Cell (PBSCs) or bone marrow cells that are CD34 selected using the CliniMACS device ENROLLMENT BY INVITATION ONLY


Eligibility criteria: Inclusion Criteria:

severe combined immune deficiency need for stem cell boost

Exclusion Criteria:

n/a

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Miami
country: United States
facility: University of Miami
state: Florida
Study officials:
affiliation: University of Miami
name: Gary Kleiner, MDPhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00427206: Hepatic Function in Alcoholics Following 5 Days of Acetaminophen Dosing
Official title: Hepatic Function Following Five Days of Therapeutic Dosing of Acetaminophen in Alcoholics
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Alcohol Related Disorders
Keywords: acetaminophen
alcohol
liver injury
Lead sponsor: Denver Health and Hospital Authority
Sponsor class: OTHER
Collaborators: name: McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
First posted: 2007-01-26
Enrollment: 181
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP

Brief summary: The study objective was to determine if liver injury develops in alcoholic patients during or following 5 days of therapeutic acetaminophen dosing. Volunteers were recruited from two community detoxification centers to take either acetaminophen (4g/day) or placebo for 5 consecutive days. All subjects were monitored an additional two days following the dosing period. The primary measures were aminotransferase measures taken at baseline and Days 2, 4, 6 and 7. We hypothesized that there would be no difference in aminotransferase means between the groups at any study period.


Eligibility criteria: Inclusion Criteria:

* 18 years and older
* admitted to participating detox facility with a positive BAL at the time of admittance
* signed a written informed consent

Exclusion Criteria:

* serum acetaminophen level greater than 20 mcg/ml
* serum AST or ALT levels greater than 200 IU/L
* INR greater than 1.5
* if female, positive for beta-subunit of chorionic gonadotropin (beta-HCG)
* clinically intoxicated, psychiatrically impaired or unable to give informed consent
* known hypersensitivity to acetaminophen
* history of ingesting more than four grams of APAP per day for any of the four days preceding study enrollment
* currently enrolled in another trial or had been enrolled in another trial in the preceding three months.

Primary outcomes:
measure: group mean aminotransferase measures
measure: mean change in aminotransferase measures between study groups
Secondary outcomes:
measure: proportion of subjects that develop an aminotransferase level greater than the upper limit of reference range
measure: proportion of subjects that develop hepatotoxicity (ALT>1000 IU/L)
measure: proportion of subjects that develop drug induced liver injury
Other outcomes:
Locations:
city: Denver
country: United States
facility: Denver CARES
state: Colorado
city: Toronto
country: Canada
facility: Centre for Addiction and Mental Health
state: Ontario
Study officials:
affiliation: Denver Health/Rocky Mountain Poison & Drug Center
name: Richard C Dart, MD, PhD
role: PRINCIPAL_INVESTIGATOR
affiliation: Centre for Addiction and Mental Health
name: Bruna Brands, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01775306: Not Invasive Monitoring at Cardiac Recompensation
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Cardiac Recompensation
Lead sponsor: RWTH Aachen University
Sponsor class: OTHER
First posted: 2013-01-24
Enrollment: 49
Sex: ALL
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with cardiac recompensation

Brief summary: The aim of this study is to find out if data can be provided by external sensor technology which is suitable for controlling the therapy of patients with cardiac recompensation.


Eligibility criteria: Inclusion Criteria:

* patients with acute or chronic cardiac decompensation with and without pulmonary oedema
* male and female patients aged at least 18 years

Exclusion Criteria:

* pregnancy or breast feeding
* implanted pacemaker / CRT / ICD exept Medtronic OptiVol
* patients being unable to consent

Primary outcomes:
measure: suitable Data
timeFrame: 15 minutes per day and per patient, 3-5 days, at most 14 days
Secondary outcomes:
Other outcomes:
Locations:
city: Aachen
country: Germany
facility: Univeristy Hospital Aachen
state: North Rhine Westfalia
Study officials:
References:
Clinical trial NCT06225206: Analysis of Donor-derived Cell Free DNA in Liver Transplant Patients
Official title: Retrospective Exploratory Analysis of Donor-derived Cell Free DNA in Liver Transplant Patients
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Liver Transplant Failure
Lead sponsor: Methodist Health System
Sponsor class: OTHER
First posted: 2024-01-25
Enrollment: 300
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: OTHER
Sampling method: PROBABILITY_SAMPLE
Study population: Patients included in the study should be at least 18 years of age, who have underwent a liver transplant and at least have one level of dd-cfDNA documented.

Brief summary: Determine the levels of Donor-derived (dd)cell-free DNA(cfDNA )in liver transplant recipients with normal liver function tests (LFTs) indicating stable immunosuppression status (IS). Based on this range use the dd-cfDNA levels to determine over or under IS in liver transplant patients to make changes to their IS medication regimen.

Detailed description: dd-cfDNA is a non-invasive method to measure graft function stability in liver transplant patients. Liver biopsy is the standard to determine liver rejection and graft function, but no tests exist currently to be able to help guide the IS regimen in these patients. LFTs are not as specific to determine graft function hence testing dd-cfDNA levels can help guide the Immunosuppression (IS )medications dosing and help identify rejection early.

Eligibility criteria: Inclusion Criteria:

1. Age: ≥18 years
2. The patient underwent a liver transplant.
3. The patient at least has one level of dd-cfDNA documented

Exclusion Criteria:

* Patient not meeting the inclusion criteria will be excluded.

Primary outcomes:
measure: dd-cfDNA range in liver transplant patients
timeFrame: 1 year
Secondary outcomes:
measure: Demographics: age (years), gender (male/female), race (Caucasian, Black, Hispanic, Asian, Other)
timeFrame: 1 year
measure: Days post-transplant at first dd-cfDNA
timeFrame: 1 year
measure: LFTs: Alanine transaminase(ALT), Aspartate transaminase(AST),Alkaline phosphatase( ALP), total bilirubin (Tbili)
timeFrame: 1 year
measure: Serum Creatinine
timeFrame: 1 year
Other outcomes:
Locations:
city: Dallas
country: United States
facility: Methodist Dallas Medical Center
state: Texas
Study officials:
affiliation: Methodist Midlothian Medical Center
name: Parvez Mantry, MD
role: PRINCIPAL_INVESTIGATOR
References: